Alterity Therapeutics Lim... (ATHE)
Kurs, die wichtigsten Kennzahlen und die neuesten Nachrichten an einem Ort.
Alterity Therapeutics Limited (ATHE) Aktienkurs, Analyse & Daten
| Geld | 3.45 |
| Marktkapitalisierung | 81.75 Mio |
| Umsatz (TTM) | 5.33 Mio |
| Nettogewinn (TTM) | -23.4 Mio |
| n/a | |
| -0.96 | |
| n/a | |
| -4.56 | |
| KBV (TTM) | 2.68 |
| KUV (TTM) | 15.35 |
| Termin Quartalszahlen | Feb 26, 2013 |
| Brief | 4.56 |
| Volumen | 11,648 |
| Ø Vol. (20D) | 44,530 |
| Eröffnung | 4.51 |
| Vortagesschluss | 4.56 |
| Tagesspanne | 4.46 - 4.83 |
| 52-Wk Range | 2.66 - 5.89 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über ATHE
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy ea...
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Alterity Therapeutics 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -12.15 Mio, ein Rückgang von -36.48 %.
FinanzberichteAnalysten erwarten einen Umsatz von ... Upgrade
vor 11 Monaten · Insider Monkey
Alterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434Alterity Therapeutics Limited (NASDAQ:ATHE) is one of the best performing ASX stocks in 2025. On September 15, the company shared data from its Phase 2 clinical trial of the drug ATH434-201 at the Ame...